Physician profile
Atinder P Panesar
NPI 1679544597
$1,904.89
in general payments reported to CMS, 2019-2025
23 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $61.45 · 2021: $19.69 · 2022: $114 · 2023: $201 · 2024: $642 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.54 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $474.34 | 2019-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $298.50 | 2019-2025 | Jynarque |
| Amgen INC. | $181.68 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $167.50 | 2024-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $121.00 | 2023-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $84.46 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $77.23 | 2023-2024 | |
| Vifor Pharma, INC. | $69.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.69 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $66.24 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $49.51 | 2025 | Ibsrela |
| Cormedix INC. | $34.72 | 2025 | Defencath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.58 | 2023-2024 | Jardiance |
| Akebia Therapeutics INC | $31.17 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.53 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $24.10 | 2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $21.27 | 2025 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $17.71 | 2024 | Crysvita |
| Novo Nordisk INC | $15.30 | 2024 | Ozempic |
| Janssen Pharmaceuticals, INC | $15.18 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.67 | 2019 | |
| Shire North American Group INC | $12.62 | 2019 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atinder Panesar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.